 Jennifer Kwak
Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 11 | 2024 | 161 | 1.360 |
Why?
| | Positron-Emission Tomography | 13 | 2024 | 343 | 1.340 |
Why?
| | Sentinel Lymph Node | 5 | 2019 | 49 | 1.100 |
Why?
| | Sentinel Lymph Node Biopsy | 6 | 2019 | 117 | 1.050 |
Why?
| | Melanoma | 9 | 2024 | 761 | 0.970 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 561 | 0.780 |
Why?
| | Fever of Unknown Origin | 1 | 2023 | 13 | 0.760 |
Why?
| | Multimodal Imaging | 6 | 2016 | 129 | 0.760 |
Why?
| | Skin Neoplasms | 6 | 2019 | 852 | 0.760 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 14 | 0.750 |
Why?
| | Radiopharmaceuticals | 11 | 2024 | 205 | 0.730 |
Why?
| | Lung Neoplasms | 10 | 2025 | 2667 | 0.660 |
Why?
| | Thyroid Neoplasms | 3 | 2020 | 370 | 0.650 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 10 | 0.650 |
Why?
| | Graves Disease | 1 | 2020 | 32 | 0.640 |
Why?
| | Four-Dimensional Computed Tomography | 5 | 2025 | 38 | 0.600 |
Why?
| | Spirituality | 1 | 2020 | 88 | 0.570 |
Why?
| | Positron Emission Tomography Computed Tomography | 6 | 2024 | 118 | 0.550 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2016 | 44 | 0.500 |
Why?
| | Iodine Radioisotopes | 4 | 2020 | 138 | 0.450 |
Why?
| | Hamartoma | 1 | 2015 | 29 | 0.430 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 159 | 0.420 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 4 | 2025 | 149 | 0.410 |
Why?
| | Tomography, X-Ray Computed | 7 | 2016 | 2770 | 0.410 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 337 | 0.360 |
Why?
| | Lymphoma | 2 | 2026 | 241 | 0.320 |
Why?
| | Radiation Pneumonitis | 2 | 2021 | 31 | 0.310 |
Why?
| | Immunotherapy | 1 | 2015 | 667 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2020 | 1150 | 0.290 |
Why?
| | Adenocarcinoma | 1 | 2016 | 926 | 0.280 |
Why?
| | Lung | 5 | 2023 | 4116 | 0.280 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 119 | 0.260 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 239 | 0.260 |
Why?
| | Lymph Node Excision | 2 | 2019 | 173 | 0.250 |
Why?
| | Respiratory-Gated Imaging Techniques | 2 | 2016 | 10 | 0.240 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 4 | 2023 | 104 | 0.230 |
Why?
| | Radioisotopes | 3 | 2024 | 37 | 0.220 |
Why?
| | alpha-MSH | 1 | 2024 | 6 | 0.210 |
Why?
| | Lutetium | 1 | 2024 | 5 | 0.210 |
Why?
| | Humans | 36 | 2026 | 145763 | 0.200 |
Why?
| | Ibuprofen | 1 | 2024 | 87 | 0.200 |
Why?
| | Computer Simulation | 2 | 2026 | 1003 | 0.190 |
Why?
| | Lymphatic Metastasis | 3 | 2019 | 336 | 0.190 |
Why?
| | Esophageal Neoplasms | 2 | 2018 | 348 | 0.190 |
Why?
| | Medical Oncology | 1 | 2026 | 340 | 0.190 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2025 | 142 | 0.180 |
Why?
| | Precision Medicine | 1 | 2026 | 461 | 0.170 |
Why?
| | Aged | 14 | 2025 | 26215 | 0.170 |
Why?
| | Methimazole | 1 | 2020 | 5 | 0.160 |
Why?
| | Antithyroid Agents | 1 | 2020 | 12 | 0.160 |
Why?
| | Retrospective Studies | 10 | 2022 | 17325 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 782 | 0.160 |
Why?
| | Machine Learning | 1 | 2026 | 587 | 0.150 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 41 | 0.150 |
Why?
| | Religion | 1 | 2020 | 65 | 0.150 |
Why?
| | Nuclear Medicine | 1 | 2019 | 9 | 0.150 |
Why?
| | Treatment Failure | 1 | 2020 | 360 | 0.150 |
Why?
| | Middle Aged | 15 | 2025 | 36302 | 0.150 |
Why?
| | Scalp | 1 | 2019 | 38 | 0.150 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 116 | 0.150 |
Why?
| | Neoplasms | 1 | 2015 | 2913 | 0.150 |
Why?
| | Thyroid Gland | 1 | 2019 | 91 | 0.140 |
Why?
| | Skin Pigmentation | 1 | 2019 | 48 | 0.140 |
Why?
| | Aged, 80 and over | 8 | 2020 | 8346 | 0.140 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2018 | 36 | 0.140 |
Why?
| | Attitude | 1 | 2020 | 259 | 0.140 |
Why?
| | Male | 19 | 2025 | 73003 | 0.130 |
Why?
| | Prognosis | 5 | 2019 | 4329 | 0.130 |
Why?
| | ROC Curve | 2 | 2018 | 618 | 0.130 |
Why?
| | Radiotherapy | 1 | 2018 | 206 | 0.130 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2016 | 288 | 0.130 |
Why?
| | Tretinoin | 1 | 2018 | 125 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 53 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 509 | 0.120 |
Why?
| | Bone Marrow | 1 | 2018 | 307 | 0.120 |
Why?
| | Female | 19 | 2025 | 79035 | 0.120 |
Why?
| | Software Validation | 1 | 2016 | 9 | 0.120 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2016 | 25 | 0.120 |
Why?
| | Neoadjuvant Therapy | 2 | 2016 | 467 | 0.120 |
Why?
| | Lung Diseases | 1 | 2023 | 782 | 0.120 |
Why?
| | Pulmonary Ventilation | 3 | 2021 | 82 | 0.120 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2016 | 70 | 0.110 |
Why?
| | Dacarbazine | 1 | 2015 | 100 | 0.110 |
Why?
| | Octreotide | 1 | 2015 | 23 | 0.110 |
Why?
| | Area Under Curve | 1 | 2016 | 332 | 0.110 |
Why?
| | Disease-Free Survival | 4 | 2019 | 770 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 266 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 119 | 0.110 |
Why?
| | Societies, Medical | 1 | 2019 | 900 | 0.110 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2014 | 8 | 0.110 |
Why?
| | Quinolines | 1 | 2015 | 190 | 0.100 |
Why?
| | Organometallic Compounds | 1 | 2015 | 113 | 0.100 |
Why?
| | Glycolysis | 1 | 2016 | 340 | 0.100 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2016 | 224 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 971 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1191 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3634 | 0.090 |
Why?
| | Adult | 9 | 2020 | 40872 | 0.090 |
Why?
| | Carcinoma | 1 | 2014 | 227 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2016 | 11793 | 0.090 |
Why?
| | Bone and Bones | 1 | 2015 | 318 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 583 | 0.090 |
Why?
| | Survival Rate | 4 | 2019 | 2094 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 1969 | 0.090 |
Why?
| | Radiotherapy Dosage | 2 | 2025 | 288 | 0.090 |
Why?
| | Inflammation | 1 | 2023 | 2883 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1582 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 2000 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 992 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 641 | 0.080 |
Why?
| | Perfusion | 2 | 2023 | 251 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.080 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 981 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 8075 | 0.060 |
Why?
| | Whole Body Imaging | 2 | 2018 | 29 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2019 | 2977 | 0.060 |
Why?
| | United States | 2 | 2022 | 16123 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2219 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2014 | 1331 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2019 | 5428 | 0.050 |
Why?
| | Cardiotoxicity | 1 | 2024 | 35 | 0.050 |
Why?
| | Albumins | 1 | 2024 | 119 | 0.050 |
Why?
| | Melanoma, Experimental | 1 | 2024 | 109 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2024 | 335 | 0.050 |
Why?
| | Algorithms | 2 | 2025 | 1850 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3915 | 0.050 |
Why?
| | Receptors, Somatostatin | 1 | 2022 | 24 | 0.050 |
Why?
| | Child | 1 | 2023 | 22739 | 0.050 |
Why?
| | Respiration | 1 | 2023 | 207 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2026 | 342 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 668 | 0.040 |
Why?
| | Pulmonary Atelectasis | 1 | 2018 | 15 | 0.040 |
Why?
| | Europe | 1 | 2019 | 421 | 0.030 |
Why?
| | Peptides | 1 | 2024 | 998 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 424 | 0.030 |
Why?
| | Thyroglobulin | 1 | 2018 | 29 | 0.030 |
Why?
| | Observer Variation | 1 | 2018 | 357 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 17 | 0.030 |
Why?
| | Axilla | 1 | 2017 | 51 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2018 | 544 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1378 | 0.030 |
Why?
| | Neck | 1 | 2017 | 109 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 3551 | 0.030 |
Why?
| | Medicare | 1 | 2022 | 904 | 0.030 |
Why?
| | Radiology | 1 | 2018 | 174 | 0.030 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2016 | 21 | 0.030 |
Why?
| | Heart | 1 | 2020 | 626 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2015 | 211 | 0.030 |
Why?
| | Fluorouracil | 1 | 2016 | 231 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 935 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 325 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1139 | 0.030 |
Why?
| | Carcinoma, Papillary | 1 | 2014 | 82 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 345 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 688 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5992 | 0.020 |
Why?
| | Preoperative Care | 1 | 2016 | 380 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2016 | 1300 | 0.020 |
Why?
| | Adolescent | 3 | 2018 | 22573 | 0.020 |
Why?
| | Research Design | 1 | 2018 | 1139 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1082 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 788 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2028 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3416 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2123 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 14251 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 981 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 6032 | 0.020 |
Why?
| | Mice | 1 | 2024 | 18355 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 4090 | 0.010 |
Why?
| | Animals | 1 | 2024 | 38097 | 0.010 |
Why?
|
|
Kwak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|